Concepedia

Author

C. Eschbach

Asklepios Klinikum Harburg

Also Known As

C E. Eschbach, C Eschbach, C. Eschbach, Chris Eschbach

30

Publications

376

Citations

7

H-Index

28

Concepts

All Affiliations

Asklepios Klinikum HarburgBoehringer Ingelheim (Germany)
CE

About

C. Eschbach is an author at Asklepios Klinikum Harburg specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

352

2

Health Sciences

3

3

197

3

Arts

1

1

30

4

Nursing

1

1

30

5

Communication

1

1

30

C. Eschbach

×

7

Publications

352

Citations

7

H-Index

YearCitations

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

Martin Reck, R. Kaiser, C. Eschbach,

Annals of Oncology

2011

149

Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study

Kenneth J. O’Byrne, Igor Bondarenko, Carlos Barrios,

Journal of Clinical Oncology

2009

92

A longitudinal communication approach in advanced lung cancer: A qualitative study of patients’, relatives’ and staff's perspectives

Matthias Villalobos, K. Coulibaly, Katja Krug,

European Journal of Cancer Care

2017

30

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial

David F. Heigener, L Freitag, C. Eschbach,

Journal of Clinical Oncology

2008

29

Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM)

Martin Reck, Maciej Krzakowski, Jacek Jassem,

Journal of Clinical Oncology

2009

19

A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)

Joachim von Pawel, R. Kaiser, C. Eschbach,

Journal of Clinical Oncology

2007

19

6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer

U. Gatzemeier, J. vonPawel, C. Eschbach,

European Journal of Cancer Supplements

2007

14

Page 1